Real-world glycemic, blood pressure, and weight control in patients with type 2 diabetes mellitus treated with canagliflozin-an electronic health-record-based study.
Canagliflozin (CANA) has been shown to improve HbA1c, blood pressure (BP), and weight in patients with type 2 diabetes mellitus (T2DM) in clinical trials. This study describes HbA1c, BP, and weight in T2DM patients treated with CANA in a real-world setting.



Adults with ≥1 diagnosis for T2DM and ≥12 months of clinical activity before the first CANA prescription (index) were identified in the IMS Health Real-World Data Electronic Medical Records - US database. Patient quality measures were described at baseline and 3, 6, 9, and 12 months post-index. Selected goals were HbA1c <7% (<53 mmol/mol), <8% (<64 mmol/mol), and >9% (>75 mmol/mol, poor control), BP <140/90 mmHg, and weight loss ≥5%.



In total, 16,163 patients were identified (mean age = 58.5 years; 47.9% female; 75.8% white). At baseline, 90.4% of patients used ≥1 anti-hyperglycemic agent. Among patients with baseline HbA1c ≥7% (n = 10,478; 64.8%; mean HbA1c = 8.8%), 21.2%, 59.5%, and 17.6% had an HbA1c <7%, <8%, and >9% after 3 months, respectively; these proportions remained stable through 12 months. Among patients with baseline BP ≥140/90, 60.0% and 75.6% attained systolic BP <140 mmHg and diastolic BP <90 mmHg after 3 months, respectively; proportions remained stable through 12 months. Weight loss ≥5% was observed in 13.3% of patients at 3 months and the proportion increased to 25.8% at 12 months.



This study relied on prescription data, which does not necessarily indicate that the medication was taken as prescribed. Some patients were also treated with other anti-hyperglycemics, anti-hypertensives, and weight loss medications during the follow-up, which may have contributed to the effects reported.



Most patients with inadequate HbA1c and BP levels at baseline achieved respective goals after 3 months of CANA, and the proportions of responders remained stable through 12 months. Weight loss ≥5% was increasingly observed over time.
a Groupe d'analyse, Ltée , Montréal , Québec , Canada ;
Patrick
P
Lefebvre
a Groupe d'analyse, Ltée , Montréal , Québec , Canada ;
Dominic
D
Pilon
a Groupe d'analyse, Ltée , Montréal , Québec , Canada ;
Marie-Noëlle
MN
Robitaille
a Groupe d'analyse, Ltée , Montréal , Québec , Canada ;
Marie-Hélène
MH
Lafeuille
b Janssen Scientific Affairs, LLC , Raritan , NJ , USA ;
Wing
W
Chow
b Janssen Scientific Affairs, LLC , Raritan , NJ , USA ;
Michael
M
Pfeifer
c Analysis Group, Inc. , Boston , MA , USA.
Mei Sheng
MS
Duh
D000328:Adult; D000368:Aged; D001786:Blood Glucose; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D000068896:Canagliflozin / Q000627:therapeutic use*; D016208:Databases, Factual; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D057286:Electronic Health Records; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies
D001786:Blood Glucose; D000068896:Canagliflozin; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents
Blood pressure; HbA1c; canagliflozin; type 2 diabetes mellitus; weight